Abstract:BACKGROUND AND PURPOSE: Hirudin variants are the most powerful thrombin inhibitors discovered to date, with a lower risk of bleeding than heparin. For anticoagulation, the C-termini of hirudin variants bind to the exocite I of thrombin. Anticoagulant effects of gene-recombinant hirudin are weaker than natural hirudin for the reason of lacking tyrosine O-sulfation at C-terminus.EXPERIMENTAL APPROACH: An integrative pharmacological study was carried out using molecular dynamic, molecular biological and in vivo and in vitro experiments to elucidate the anticoagulant effects of protein-engineered hirudins.KEY RESULTS: Molecular dynamic analysis showed that modifications of the C-termini of hirudin variant 1 of Hirudo medicinalis (HV1) and hirudin variant 2 of Hirudinaria manillensis (HM2) changed the binding energy of the C-termini to human thrombin. The study indicated that Asp61 of HM2 that corresponds to sulfated Tyr63 of HV1 is critical for inhibiting thrombin activities. Further, the anticoagulant effects of HV1 and HM2 were improved when the amino acid residues adjacent to Asp61 were mutated to Asp. These improvements were prolongation of the activated partial thromboplastin time, prothrombin time and thrombin time of human blood, and decreased K<sub>i</sub> and IC<sub>50</sub> values. In the in vivo experiments, mutations at C-termini of HV1 and HM2 significantly changed partial thromboplastin time, prothrombin and thrombin time CONCLUSION AND IMPLICATIONS: The study indicated that the anticoagulant effects of gene-engineered HM2 are stronger than gene-engineered HV1 and HM2-E60D-I62D has the strongest effects and could be an antithrombotic with better therapeutic effects.

Molecular cloning of hirudin derivative cDNA gene and expression in mammalian cell

Cloning, characterization, and heterologous expression of a candidate Hirudin gene from the salivary gland transcriptome of Hirudo nipponia

Study on the Cloning and Expression of Human Fibrinogen α ,β, γ Gene

Synthesis of Hirudin Gene by Recursive PCR and Its Expression and Secretion in Escherichia Coli

Molecular dynamic and pharmacological studies on protein‐engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis

Study on the Cloning and Expression of Human Fibrinogen Α,β,γ Gene

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Cloning and Expression of Tachypleus Tridentatus Factor C

Expression and affinity purification of small molecule functional peptide of Hirudin in E. coli

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Expression, Purification and Characterization of Recombinant Targeting Bifunctional Hirudin in Pichia Pastoris

[Fermentation, Purification and Identification of Recombinant RGD-Hirudin].

Preparation and Biological Activity Assay of Recombinant Reversible Hirudin

Construction, Expression, and Characterization of Recombinant Hirudin in Escherichia Coli.

Construction and Expression of Chimeric Antithrombotics with Hirudin and RGD Sequence

[Cloning Expression and Characterization of a Multifunctional Anticoagulated Peptide Gene in E. Coli].

Identification and Characterization of Hirudin-Hn, a New Thrombin Inhibitor, from the Salivary Glands of Hirudo Nipponia

Construction of a Eukaryotic Expression Vector Hvegf_(165)-Fused Hirudin/pcdna3.0 and Its Expression

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function

Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-hirudin, Expressed in Pichia Pastoris, for NMR Studies.

Cell-free synthesis of the hirudin variant 1 of the blood-sucking leech Hirudo medicinalis